23 January 2020
Visiongain’s new report the Ophthalmology PCAS Market Report 2020-2030: Forecasts by Type (stand alone and integrated), by Delivery Mode (cloud based and on premises) by End Use (Hospitals and Specialty Clinics) plus analysis of leading companies indicates that the global ophthalmology PCAS market will grow at a CAGR over 5% by 2030.
Increasing the use of teleophthalmology solutions due to the lack of professional ophthalmologists and optometrists are key drivers of market growth. Moreover, significant growth in Information Technology (IT) and its rising impact on the ophthalmology practices is anticipated to drive the market. In addition, high prevalence of diabetes and eye disease such as Diabetic Macular Edema (DME), diabetic retinopathy, cataract, and glaucoma are likely to boost the sector. For example, according to a report carried out by the International Diabetes Federation (IDF), some 3.27 million diabetes cases were diagnosed in France in 2017.
Increasing the burden of ophthalmic disease, high unmet medical needs in emerging economies, and increased spending on public and private health care to improve vision care services would fuel demand further. In addition, increased demand for early and reliable methods of detection is expected to fuel market growth in the coming years. Electronic Health Record (EHR) and Electronic Medical Record (EMR) programs provide healthcare service providers with complete and accurate information to help improve treatment and reducing medical errors. Government organizations will therefore take initiatives to encourage the adoption of EHR and EMR to further use ophthalmic PACS systems for fuel. The segment of Integrated Systems held the major share of the global market for PACS ophthalmology.
Such systems incorporate medical applications such as integration of data, functional integration, context integration, and integration of presentation. The diagnostic tool systems thus provide physicians with the ability to monitor medical records and test tests from anywhere and at any time. Advances in the segment's technology and service will further boost growth in the near future. Heidelberg Engineering, for example, unveiled SPECTRALIS glaucoma and retina imaging system in November 2015.
Features provided by integrated systems such as ease of understanding, good user interface, data portability, protection, cost-effectiveness and ease of deployment will provide additional fuel consumption. During the forecast period, the cloud-based system category is expected to experience the highest CAGR. Cloud-based systems provide doctors with ability to access medical records from anywhere and at any time. As a result, healthcare providers around the world are now using these devices for image delivery, monitoring, imaging research, and redundant data processing. Working with major market leaders and hospitals and clinics to offer innovative PACS technologies and services can accelerate hospital adoption. Sectra, an international medical imaging IT provider, and ProMedica, a U.S. hospital chain, signed a six-year deal to provide PACS services to ProMedica, for instance, in April 2016.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.